<DOC>
	<DOCNO>NCT00020410</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Peripheral stem cell transplantation may allow doctor give high dos monoclonal antibody therapy kill cancer cell . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody follow peripheral stem cell transplantation treat patient relapse metastatic breast cancer .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Followed Peripheral Stem Cell Transplantation Treating Patients With Relapsed Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose yttrium Y 90 monoclonal antibody B3 follow autologous peripheral blood stem cell transplantation patient relapse metastatic breast cancer . - Determine toxicity treatment regimen patient . - Determine clinical response patient treat regimen . OUTLINE : This dose-escalation study yttrium Y 90 monoclonal antibody B3 ( Y90 MOAB B3 ) . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin 4 day prior peripheral blood stem cell ( PBSC ) collection continue target number cell reach . After PBSC collection , patient receive indium In 111 monoclonal antibody B3 IV 30-60 minute within day -7 -1 tumor image Y90 MOAB B3 IV 30-60 minute day 0 . After least day 7 , patient undergo autologous PBSC reinfusion . Patients receive G-CSF SC daily begin 7 day PBSC reinfusion continue blood count recover . Cohorts 3-6 patient receive escalate dos Y90 MOAB B3 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 1 week , 1 month , every 2 month thereafter . PROJECTED ACCRUAL : A total 20-30 patient accrue study within 24-36 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IV breast cancer At least 1 site relapse metastatic disease Progressive disease least 1 prior chemotherapy regimen metastatic disease One regimen must contain anthracycline taxane adjuvant therapy metastatic disease Prior adjuvant chemotherapy allow Measurable evaluable disease Tumor tissue must express B3 antigen surface 30 % tumor cell No CNS metastasis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count great 2,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin normal SGOT SGPT great 2 time upper limit normal PT normal Hepatitis B surface antigen negative Hepatitis C negative Renal : Creatinine great 1.4 mg/dL Cardiovascular : Ejection fraction least 45 % MUGA echocardiogram Pulmonary : FEV_1 great 60 % predict FVC least 55 % predict DLCO least 55 % predict Other : No known seizure disorder No history autoimmune disease No active malignancy except previously treat basal cell skin cancer No concurrent medical psychiatric condition would preclude study participation HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Chemotherapy No prior mouse antibody Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No prior highdose chemotherapy bone marrow stem cell transplantation Endocrine therapy : At least 4 week since prior hormonal therapy No concurrent chronic steroid Radiotherapy : At least 4 week since prior local radiotherapy one site recover No prior radiotherapy pelvis and/or spine Surgery : Not specify Other : No concurrent anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>